Nath Bio-Genes (India) Ltd - 537291 - NBIL Concall
Nath Bio-Genes informed that the audio recording of the conference call held on May 5, 2026, is available on its website. The call discussed the audited financial results for Q4 FY26 and year ended March 31, 2026.
May 11 2026 16:05:00
Nath Bio-Genes (India) Ltd - 537291 - Board Meeting Outcome for Outcome Of Board Meeting
Nath Bio-Genes reported strong FY26 cons. results: revenue climbed 22% to ₹445.10 crore, and net profit increased 8% to ₹41.63 crore. The board recommended a final dividend of ₹2 per share and approved the reappointment of Mr. Hitesh Rajnikant Purohit as Independent Director for a second 5-year term.
May 04 2026 17:05:00
Nath Bio-Genes (India) Limited
Nath Bio-Genes board to meet on May 4, 2026, to approve audited financial results for Q4 and FY26. The meeting will also consider a dividend recommendation for 2025-26, subject to shareholder approval.
Apr 25 2026 20:04:00
Nath Bio-Genes (India) Limited
Nath Bio-Genes board to meet on May 4, 2026, to consider and approve audited quarterly financial results for Q4 FY26 and recommend a final dividend. The results will be both standalone and cons. The dividend recommendation is subject to shareholder approval.
Apr 25 2026 20:04:00
Nath Bio-Genes (India) Limited
Nath Bio-Genes (India) Limited disclosed that 13.78% of its promoter and promoter group shares are pledged. This amounts to 6.28% of the company's total shares as of March 31, 2026, raising concerns about promoter liquidity or the company's financial health.
Apr 21 2026 11:04:00
Read More